Beyond the AI Hype: Yidu Tech Builds the Rails for a Health Tech Revolution

DALIAN, China – June 24, 2026 – As the tech world grapples with a palpable sense of “AI fatigue,” investors are increasingly shifting their focus from dazzling demos to durable business models. The central question in the 2026 landscape is no longer what AI can do, but what it is doing to generate real value. It’s a search for the picks and shovels behind the gold rush, and this week at the World Economic Forum’s Summer Davos, Yidu Tech’s Founder and Chairlady, Gong Yingying, made a compelling case that her company is building the foundational rails for the entire health tech ecosystem.

On a panel titled “Faster Drugs, Better Access?”, alongside heavyweights from Novartis and Peking University, Gong steered the conversation away from abstract AI capabilities toward the gritty, unglamorous work of data infrastructure. While the market is saturated with companies touting proprietary algorithms, Yidu Tech has spent over a decade focused on a more fundamental problem: the fragmented, inconsistent, and disconnected nature of healthcare data. This infrastructure-first approach, once seen as a slow and costly endeavor, is now emerging as a powerful catalyst for market momentum and a significant competitive moat.

The ‘Evidence Layer’: More Than Just Data

The core of Yidu Tech’s strategy, and the primary driver of its value proposition, is the creation of what Gong calls an “evidence layer.” This isn’t just another big data repository; it’s a meticulously constructed foundation built from raw, chaotic medical information. “Data is scattered, inconsistent, and disconnected,” Gong noted at the forum, identifying this as the single biggest barrier to AI’s potential in medicine. The company’s solution has been to build a four-layer architecture that culminates in a high-quality, standardized data pool where information becomes traceable, verifiable, and structured evidence.

This is the engine behind YiduCore, the company’s proprietary “AI Medical Brain.” The scale is staggering: as of late 2025, the platform had processed and analyzed nearly 7 billion authorized medical records from a network of over 10,000 healthcare entities, including deep partnerships with over 110 of China’s top hospitals. By transforming this fragmented data into a coherent disease knowledge graph, YiduCore provides the essential groundwork for developing responsible and effective AI applications. It’s a crucial distinction; rather than simply applying a model to raw data, the company first ensures the data itself is trustworthy.

The practical impact on the pharmaceutical industry is profound. For an industry plagued by decade-long development timelines and staggering costs, this infrastructure offers tangible efficiencies. Company reports and analyst estimates suggest Yidu’s platform can improve clinical trial efficiency by up to 40% and reduce associated costs by 30% to 50%. It achieves this by accelerating patient recruitment through intelligent matching, optimizing trial design to reduce failure risk, and enabling real-time monitoring to ensure data quality and compliance. What was once considered a value-added service is now, as Gong argued, an essential prerequisite for high-quality clinical research.

From Theory to Profitability: A Market Inflection Point?

For investors, the most compelling evidence of Yidu Tech’s success lies not in its technology but on its balance sheet. The company is on the cusp of a major inflection point, projecting its first-ever annual profit for the fiscal year that ended in March 2026. After a decade of heavy investment in its data infrastructure, Yidu Tech anticipates a net profit between $6 million and $8.2 million, a sharp reversal from the previous year's loss. This long-awaited shift to profitability signals that the company’s strategy of building foundational infrastructure is finally bearing financial fruit.

This isn't just a story about one company's turnaround; it may represent a maturation of the entire healthcare AI sector. The market is rewarding tangible outcomes and validated use cases. Yidu Tech’s recent contract win in May 2026 to build an intelligent clinical research platform for the prestigious Tianjin Medical University Cancer Institute and Hospital is a powerful testament to this. It demonstrates clear market demand and a willingness from major healthcare institutions to invest in these systems. This, combined with Frost & Sullivan recognizing the company as the market share leader in China's healthcare intelligence sector, provides strong validation.

With 280 AI agents already deployed in clinical settings—some being used nearly 1,000 times a day by physicians in client hospitals—the adoption metrics are undeniable. The company is successfully embedding its tools into the daily workflows of healthcare professionals, moving from a peripheral technology to a core operational component.

A Blueprint for Global AI: Data Sovereignty in Practice

As tech giants face growing scrutiny over data privacy and geopolitical tensions complicate global operations, Yidu Tech’s international expansion strategy offers a nuanced and potentially more sustainable blueprint. The company’s approach is rooted in a deep respect for data sovereignty and a commitment to “deep localization.”

The most telling example is its joint venture in Brunei to co-manage BruHealth, the nation’s digital health platform. Instead of imposing a standardized global product, Yidu Tech partnered with the government, formed a shared technical team, and built a system tailored to local public health needs while ensuring all data remained under sovereign control. This model acknowledges that healthcare is not a one-size-fits-all industry; it is intrinsically tied to local regulations, culture, and policy.

This strategy is not only ethically sound but also strategically brilliant. It de-risks international expansion by building trust with local governments and regulators from the outset. As the company eyes further expansion into Japan, Europe, and the U.S., this proven ability to navigate complex data governance frameworks will be a critical competitive advantage, offering a clear and compliant path to market entry where others may falter.

Navigating China's Health Tech Ascent

Yidu Tech’s rise is inseparable from the broader narrative of China’s strategic push into health technology. National initiatives like “Healthy China 2030” and the 14th Five-Year Plan have created a fertile ground for companies that can leverage AI and big data to solve systemic healthcare challenges. Yidu Tech appears to be perfectly aligned with these national priorities.

In late 2025, the company secured two major research projects from the National Healthcare Security Administration, focusing on AI-assisted data governance. This indicates a high level of trust from key government bodies and positions the company as a crucial partner in the nation's ambitious healthcare modernization plans. By building systems that ensure traceability, explainability, and compliance, Yidu Tech is not just meeting regulatory requirements; it is actively shaping the infrastructure that will underpin the future of China's healthcare system.

For those looking for the why behind the buy, Yidu Tech presents a compelling case. It is a story of a company that resisted the allure of short-term hype to build the essential, long-term infrastructure the industry needs. Its impending profitability, validated market leadership, and savvy global strategy suggest that the quiet work of laying down the tracks is about to pay off, powering a new wave of data-driven medical innovation.